Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.
Martin J. van den Bent(Erasmus MC Cancer Institute), Brigitta G. Baumert(Kantonsspital Graubünden), Warren Mason(Princess Margaret Cancer Centre), Anna K. Nowak(The University of Western Australia), Michael Weller(University Hospital of Zurich), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Sara Erridge(The University of Texas MD Anderson Cancer Center), Helen Wheeler(The University of Sydney), Ken Aldape(The University of Texas MD Anderson Cancer Center), Marc Sanson(Centre National de la Recherche Scientifique), Johan M. Kros(Erasmus MC), Olivier Chinot(Aix-Marseille Université), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Vassilis Golfinopoulos(Champalimaud Foundation), Paul M. Clément(Universitair Ziekenhuis Leuven), Michael A. Vogelbaum(Moffitt Cancer Center), Winand N.M. Dinjens(Erasmus MC)
Cited by 34
Related Papers
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
|Nature|2008|7.8k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k